期刊文献+

安福隆联合利巴韦林治疗慢性丙型病毒性肝炎肝硬化失代偿期一例

下载PDF
导出
摘要 患者女性,47岁,已婚,下岗工人。因乏力、纳差、腹胀7d.以丙型病毒性肝炎肝硬化失代偿期于2006年9月27日住院。无其他疾病史。曾于1989年行剖宫产.输血400ml。2004年体检发现抗-HCV阳性,肝功能轻度异常,未做任何治疗。2006年5月因腹胀,在某院诊断为“丙型病毒性肝炎肝硬化失代偿期”。给予还原谷胱甘肽、人血白蛋白等药物治疗.住院30余天,病情好转出院。之后在家服用中药治疗。来笔者医院时,患者神志清楚,面色晦暗。查体:皮肤无黄染,无蜘蛛痣,巩膜无黄染,心肺功能正常.腹部轻度膨隆,无腹壁静脉曲张,肝脾未触及,移动性浊音阳性,其余正常。
出处 《生物医学工程与临床》 CAS 2007年第6期485-485,共1页 Biomedical Engineering and Clinical Medicine
  • 相关文献

参考文献3

二级参考文献13

  • 1Sandler SR, Karo W, ed. Polymer Syntheses. New York: Academic Press, 1980, 3. 138-161.
  • 2Katre NV, Knauf MJ, Laird WJ. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA, 1987, 84: 1487-1491.
  • 3Carpenter CP, Woodside MD, Kinkead ER, et al. Response of dogs to repeated intravenous injection of polyethylene glycol 4000. Toxicol Appl Pharmacol, 1971, 18: 35-40.
  • 4Abuchowski A, Davis FF. Soluble Polymer-enzyme adducts. In: Holcenberg JC, Ed. Enzymes as drugs. New York: Wiley and Sons Inc, 1981. 367-383.
  • 5Knauf MJ, Bell DP, Hirtzer P, et al. Relationship of effective molecularsize to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem, 1988, 263: 15064-15070.
  • 6Savoca K, Wieder K. Modified enzymes with unique properties. In: GB Broun, et al. Eds. Enzyme-Polyethylene glycol adducts. Vol 4. New York: Enzyme Engineering, Plenum Press. 1978. 169-173.
  • 7Mur RE. Preliminary clinical results of combination pegylated interferon α-2b plus ribavirin. In: 35th Annual meeting of the European Association for the Study of the liver. 2000, 19.
  • 8Heathcote EJ, Pockros P, Fried M, et al. The pharmacokinetics of pegylated-40 K interferon in chronic hepatitis C patients with cirrhosis. Gastroen-terology, 1999, 116(Pt2): 3190.
  • 9Glue P. Clinical pharmacology of pegylated Interferon α-2b. In: 35th Annual meeting of the European Association for the Study of the Liver. 2000, 13.
  • 10Schiffman M, Pockros PJ, Reddy RK, et al. A controlled, randomized multicenter, descending dose phase Ⅱ trial of pegylated interferon α-2a(PEG) vs standard interferon α-2a(IFN) for treatment of chronic hepatitis C. Gastroenterology, 1999, 116(Pt2): 1275.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部